[1]段炼,陆克义,陈霞,等.131I治疗Graves病对甲状腺相关眼病转归的相关因素分析[J].国际放射医学核医学杂志,2011,35(4):230-234.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
　DUAN Lian,LU Ke-yi,CHEN Xia,et al.Related factors of thyroid-associated ophthalmopathy in patents with Graves’ disease after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):230-234.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
点击复制

131I治疗Graves病对甲状腺相关眼病转归的相关因素分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第4期
页码:
230-234
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Related factors of thyroid-associated ophthalmopathy in patents with Graves’ disease after 131I treatment
作者:
段炼1;  陆克义2;  陈霞2;  李险峰3;  孙斌4;  赵德善2;  刘建中2;  李思进2
1. 山西长治医学院附属和平医院核医学科, 山西 046000;
2. 山西医科大学第一医院核医学科, 太原 030001;
3. 山西医科大学第一医院放疗科, 太原 030001;
4. 山西医科大学第一医院眼科, 太原 030001
Author(s):
DUAN Lian1;  LU Ke-yi2;  CHEN Xia2;  LI Xian-feng3;  SUN Bin4;  ZHAO De-shan2;  LIU Jian-zhong2;  LI Si-jin2
Department of Nuclear Medicine, Department of Nuclear Medicine, Heping Hospital of Changzhi Medical College, Shanxi Changzhi 046000, China
关键词:
格雷夫斯病; 碘放射性同位素; Graves眼病; 因素分析; 统计学
Keywords:
Graves disease; Iodine radioisotopes; Graves ophthalmopathy; Factors analysis; statistical
DOI:
10.3760/cma.j.issn.1673-4114.2011.04.009
摘要:
目的 分析Graves病131I治疗后甲状腺相关眼病(TAO)转归的相关影响因素。方法 对562例131I治疗的Graves病患者进行随访研究,其中,131I治疗前伴TAO的患者243例,未伴TAO的患者319例。随访观察TAO的好转、无变化及进展三级转归情况,进行有序多分类Logistic回归分析。结果 随访的未伴TAO的患者中,出现10例新发TAO(3.13%);伴TAO的243例中,好转134例(55.14%),无变化99例(40.74%),进展10例(4.12%)。伴TAO与不伴TAO的Graves病进展率差异无统计学意义(χ2=0.576,P>0.05),单纯性突眼组与浸润性突眼组间患者的进展率差异有统计学意义(χ2=11.893,P<0.05),其好转率差异亦有统计学意义(χ2=10.621,P<0.05)。131I治疗后,TAO的转归及各相关因素经有序多分类Logistic回归分析显示,131I治疗前,吸烟史、促甲状腺素水平、TAO的分类、治疗后甲状腺功能异常是131I治疗后TAO转归的危险因素,131I治疗后,合用强的松是TAO转归的保护因素。结论 131I治疗对Graves病伴或不伴TAO患者的进展无明显影响,且早期控制危险因素,合理应用强的松有利于TAO的转归。
Abstract:
Objective To analysis the related factors of thyroid-associated ophthalmopathy(TAO) in patients with Graves’ disease after 131I treatment. Methods Five hundred and sixty two patients with Graves’ disease were followed up after 131I treatment, included 243 cases with TAO and 319 cases without TAO. Logistic multivariate regression analysis was used to analyse the data of the improvement of the TAO, stablity and progression. Results Of the patients without TAO, 10 new cases of TAO were diagnosed(3.13%). Of the paitents with TAO, 134(55.14%) had experienced improvement, 99(40.74%) cases with stable disease and 10(4.12%) cases with progressed disease. The progression rate were no difference between the part of patients with and without TAO(χ2=0.576, P>0.05), and were difference between simple and invasive prominent eyes groups(χ2=11.893, P<0.05). The rate of improvement between simple and invasive prominent eyes groups also had statistical significance(χ2=10.621, P<0.05). By Logistic analysis, the history of smoking, low levels of TSH, severity of TAO, and dysfunction of thyroid were risk factors of deterioration of TAO, treatment with glucocorticoid is protection factors. Conclusion 131I therapy had no obviously influence between Graves’ disease with and without TAO, and early controling the risk factors and treatment with glucocorticoid could prevent aggravation of TAO.

参考文献/References:

[1] Cheviot L,Fiore E,Vitter P,et al.Outcome of thyroid function in Graves’ patients treated with radioiodine:role of thyroid-stimulating and thyrotrophic-blocking antibodies and of radioiodine-induced thyroid damage,J Clin Endocrinol Metab,1998,83(1):40-46.
[2] Van Dyk HJ.Orbital Graves’ diseases.A modification of the "NO SPECS" classication.Ophthalmology,1981,88(6):479-483.
[3] Hamilton HE,Schultz RO,De Gowin EL.The endocrine eye lesion in hyperthyroidism.Its incidence and course in 165 patients treated for thyrotoxicosis with iodine.Arch Intern Med,1960,105:675-685.
[4] Werner SC,Coelho B,Ouimby EH.Ten year results of 1-131 therapy in hyperthyroidism.Bull N Y Acad Med,1957,33(11):783-806.
[5] Bartalena L,Martino E,Marcocci C,et al.More on smoking habits and Graves’ ophthalmopathy.J Endocrinol Invest,1989,12(10):733-737.
[6] Tellez M,Cooper J,Edmonds C.Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin.Clin Endocrinal(Oxf),1992,36(3):291-294.
[7] Bonnema SJ,Bartalena L,Toft AD,et al.Controversies in radioiodine therapy:relation to ophthalmopathy,the possible radioprotective effect of antithyroid drugs,and use in large goitres.EurJ Endocrinol,2002,147(1):1-11,
[8] 段炼,李险峰,陆克义,等.99Tcm-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用.中华眼科杂志,2006,42(12):1068-1072.
[9] Acharya SH,Avenell A,Philip S,et al.Radioiodine therapy(RAI) for Graves’ disease(GD) and the effect on ophthalmopathy:a systematic review.Clin Endocrinol(Oxf),2008,69(6):943-950.

相似文献/References:

[1]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[4]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[5]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[8]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
　Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
[9]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[10]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[15]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[16]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[17]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(4):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[18]牟联超,李先映,石彩虹.131I治疗青少年Graves病58例临床分析[J].国际放射医学核医学杂志,2010,34(5):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
　MU Lian-chao,LI Xian-ying,SHI Cai-hong.Analyze of 131I therapy on 58 youngsters with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
[19]查金顺,黄春玲,蒋婷吟,等.131I治疗Graves甲状腺功能亢进症中碳酸锂的应用[J].国际放射医学核医学杂志,2011,35(2):93.[doi:10.3760/cma.j.issn.1673-4114.2011.02.007]
　ZHA Jin-shun,HUANG Chun-ling,JIANG Ting-yin,et al.Application of lithium carbonate on radioiodine treatment of Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):93.[doi:10.3760/cma.j.issn.1673-4114.2011.02.007]
[20]钟兴祥,郑吉祥,蓝冠章,等.Graves甲亢131I治疗前后血清TRAb动态变化及临床价值[J].国际放射医学核医学杂志,2011,35(2):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
　ZHONG Xing-xiang,ZHENG Ji-xiang,LAN Guan-zhang,et al.Changes of serum TRAb after 131I radiotherapy in patients of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]

备注/Memo

备注/Memo:
收稿日期:2011-04-01。
通讯作者:李险峰(Email:lixianfeng-lxf@263.net)
更新日期/Last Update: 1900-01-01